Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($1.02), $0.17 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $17 million versus the consensus estimate of $31.61 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.